



Rec'd PAT/PTO 15 OCT 2004

PCT/GB 2003 / 0 0 1 5 3 6



INVESTOR IN PEOPLE

## PRIORITY DOCUMENT

SUBMITTED OR TRANSMITTED IN  
COMPLIANCE WITH RULE 17.1(a) OR (b)

The Patent Office  
Concept House  
Cardiff Road  
Newport  
South Wales  
NP10 8QQ

REC'D 0 4 JUN 2003

WIPO


PCT

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



*P. Mahoney*

Signed

Dated 9 May 2003

An Executive Agency of the Department of Trade and Industry

**BEST AVAILABLE COPY**

Patents Form 1/77

Patents Act 1977  
(Rule 16)The  
Patent  
Office17APR02 E711815-1 002866  
P01/7700 0.00-0208785.6

1/77

**Request for grant of a patent***(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)*THE PATENT OFFICE  
A  
17 APR 2002  
RECEIVED BY FAX

The Patent Office

Concept House  
Cardiff Road  
Newport  
South Wales  
NP10 8QQ

1. Your reference ARDW / P25932GB

2. Patent application number  
(The P-  
0208785.6

17 APR 2002

3. Name and postcode of the or of  
applicant (underline all surnames)Medical Research Council  
20 Park Crescent  
London  
W1B 1AL  
United Kingdom

Patents ADP number (if you know it)

If the applicant is a corporate body, give the  
country/state of its incorporation

United Kingdom

596007001

4. Title of the invention

TREATMENT METHODS

5. Name of your agent (if you have one)

ERIC POTTER CLARKSON  
PARK VIEW HOUSE  
58 THE ROPEWALK  
NOTTINGHAM  
NG1 5DD"Address for service" in the United Kingdom  
to which all correspondence should be sent  
(including the postcode)

Patents ADP number (if you know it)

1305010 ✓

6. If you are declaring priority from one or more  
earlier patent applications, give the country  
and the date of filing of the or of each of these  
earlier applications and (if you know it) the or  
each application number

Country

Priority application number  
(if you know it)Date of filing  
(day / month / year)7. If this application is divided or otherwise  
derived from an earlier UK application, give  
the number and the filing date of the earlier  
application

Number of earlier application

Date of filing  
(day / month / year)8. Is a statement of inventorship and of right to  
grant of a patent required in support of this  
request? (Answer 'Yes' if:

YES

- a) any applicant named in part 3 is not an inventor; or
  - b) there is an inventor who is not named as an applicant; or
  - c) any named applicant is a corporate body.
- See note (d))

Patents Form 1/77

## Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form

Description 40

Claims(s) 6

Abstract 1

Drawing(s) 5

10. If you are also filing in any of the following, state how many against each item.

Priority Documents 0

Translations of priority documents 0

Statement of inventorship and right to grant of a patent (Patents Form 7/77) NO

Request for preliminary examination and search (Patents Form 9/77) YES

Request for substantive examination (Patents Form 10/77) NO

Any other documents  
(please specify)

11.

I/We request the grant of a patent on the basis of this application.

Signature

ERIC POTTER CLARKSON

Date

17 April 2002

12. Name and daytime telephone number of person to contact in the United Kingdom

0115 9552211

## Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

## Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 01645 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- For details of the fee and ways to pay please contact the Patent Office.

Patents Form 1/77

## TREATMENT METHODS

The present invention relates to methods of treatment, and in particular methods of treating uterine pathological conditions.

Pathological conditions of the uterus represent a serious health problem in women, particularly women of the western world. Such pathological conditions include uterine carcinoma, and endometrial or myometrial pathological conditions such as endometriosis (endometrial) and fibroids (myometrial).

The FP prostaglandin receptor has been studied in a variety of tissues including the bovine corpus luteum (Sharif *et al* 1998, *J. Pharmacol. Exp. Ther.* 286: 1094-1102); human uterus (Senior *et al* 1992, *Br. J. Pharmacol.* 108: 501-506); rabbit jugular vein (Chen *et al* 1995, *Br. J. Pharmacol.* 116: 3035-3041); various human ocular tissues (Davis & Sharif 1999, *J. Ocular Pharmacol. Ther.* 15: 323-336); and in mouse Swiss 3T3 fibroblasts (Griffin *et al* 1997, *J. Pharmacol. Exp. Ther.* 281: 845-854); and in rat vascular smooth muscle cells (A7r5) Griffin *et al* 1998, *J. Pharmacol. Exp. Ther.* 286: 411-418).

Potent, selective synthetic agonists at some prostaglandin receptors have been characterised in both *in vitro* and *in vivo* models (Coleman *et al* 1994, *Pharmacol. Rev.* 46: 205-229). For instance fluprostenol or its enantiomer (eg AL-5848) (Sharif *et al.* 1999, *J. Pharm. Pharmacol.*, 51: 685-694) and cloprostenol (Coleman *et al* 1994; Sharif *et al* 1998) are potent and selective FP receptor agonists. Since most natural prostaglandins show rather limited selectivity for their preferred receptor among this receptor family, the few reported selective prostaglandin receptor agonists have been very valuable tools for discriminating discrete functional responses coupled to their respective receptors. However, conclusive identification of the particular receptors mediating prostaglandin-stimulated functional responses requires potent and selective antagonists (Kenakin 1996, *Pharmacol. Rev.* 48: 413-463).

The recent identification and commercial development of selective FP receptor agonists as potent and highly efficacious drugs for the treatment of elevated intraocular pressure (Bito 1997, *Surv. Ophthalmol.* 41 (Suppl. 22): S1-S14; Hellberg *et al* 1998, *Invest. Ophthalmol. Vis. Sci.* 39 (Suppl.): 1961) has considerably advanced our knowledge of FP receptor-coupled pharmacological actions. However, the function of the FP receptor is not fully understood, due in part to significant species differences in the tissue distribution of this receptor (Ocklind *et al* 1996, *Invest. Ophthalmol. Vis. Sci.* 37: 716-726; Davis & Sharif 1999; Sharif *et al* 1999).

Griffin *et al* (*J. Pharmacol. Exp. Ther.* 1999, 290: 1278-1284) reported the discovery of a selective FP receptor antagonist (AL-8810) of micromolar potency. Sharif *et al* (*J. Pharm. Pharmacol.* 2000, 52: 1529-1539) describe another analogue of PGF<sub>2α</sub> (AL-3138; Ro-22-6641; 11-deoxy-16-fluoro PGF<sub>2α</sub>) which is a partial agonist of low efficacy and which also functions as an FP receptor antagonist. AL-3138 being a relatively selective agent may be a valuable FP receptor antagonist tool for investigating the specific function of the FP receptor in various biological systems.

Cyclooxygenase (COX) enzymes, also called prostaglandin endoperoxide synthase (PGHS), catalyse the rate limiting step in the conversion of arachidonic acid to prostaglandin H<sub>2</sub> (PGH<sub>2</sub>). In turn PGH<sub>2</sub> serves as a substrate for specific prostaglandin synthase enzymes that synthesise the natural prostaglandins. These are named according to the prostaglandin they produce such that prostaglandin D<sub>2</sub> is synthesised by prostaglandin-D-synthase, prostaglandin E<sub>2</sub> (PGE<sub>2</sub>) by prostaglandin-E-synthase (PGES) and prostaglandin F<sub>2α</sub> (PGF<sub>2α</sub>) by prostaglandin-F-synthase (PGFS). To date, there are two identified isoforms of the COX enzyme, COX-1 and COX-2 (DeWitt, 1991). COX-1 is constitutively expressed in many tissues and cell types and generates prostaglandins for normal physiological function (Herschman, 1996). By contrast, the expression of COX-2 is rapidly induced following stimulation of quiescent cells by growth

factors, oncogenes, carcinogens and tumour-promoting phorbol esters (Herschman, 1996; Subbaramaiah *et al.*, 1996).

PGE<sub>2</sub> mediates its effect on target cells through interaction with different isoforms of seven transmembrane G protein coupled receptors (GPCR) which  
5 belong to the rhodopsin family of serpentine receptors. Four main PGE<sub>2</sub> receptor subtypes have been identified (EP1, EP2, EP3 and EP4) which utilise alternate and in some cases opposing intracellular signalling pathways (Coleman *et al.*, 1994). This diversity of receptors with opposing action may confer a homeostatic control on the action of PGE<sub>2</sub> that is released in high concentrations  
10 close to its site of synthesis (Ashby, 1998). To-date, the role of the different PGE<sub>2</sub> receptors, their divergent intracellular signalling pathways, as well as their respective target genes involved in mediating the effects of PGE<sub>2</sub> on normal or neoplastically transformed endometrial epithelial cells remain to be elucidated.

Epithelial cells of the human endometrium are highly vulnerable to neoplastic  
15 transformation. In the western world, endometrial carcinoma is the most common gynaecologic malignancy. Endometrial cancer can arise from several cell types but the glandular epithelium is the most common progenitor (adenocarcinomas account for 80-90% of uterine tumours). Endometrial cancer is predominantly a post-menopausal disease where incidence is uncommon  
20 below the age of forty and peaks by about seventy years of age. The incidence of endometrial cancer has been increasing steadily in the western world during the last fifty years and this has been attributed largely to increased life expectancy and improved detection methods (Gordon & Ireland, 1994; Mant & Vessey, 1994).

25 We have shown that expression of the PGF<sub>2α</sub> receptor in the uterus across the menstrual cycle demonstrates higher level of the receptor during the proliferative phase of the endometrium compared with other stages. Expression in uterine carcinoma tissue is significantly elevated compared with normal uterine tissue. Using an endometrial epithelial cell line, we have demonstrated

that  $\text{PGF}_{2\alpha}$  induces proliferation of epithelial cells. This proliferation can be inhibited by using specific inhibitors of the PLC signalling pathway.

These observations demonstrate the possibility of antagonising the  $\text{PGF}_{2\alpha}$  (FP) receptor to combat pathological conditions of the uterus, such as to reduce the proliferation of epithelial cells in uterine carcinoma.

Antagonists of the FP receptor have been suggested for treating or preventing premature delivery of a foetus and dysmenorrhea, acting by the mechanism of relaxation of smooth muscle (WO 99/32640 and WO 00/17348). They have not, however, been previously suggested to be useful in combating uterine pathological conditions, such as uterine cancers, endometriosis or fibroids.

Current treatment of uterine pathologies includes the use of COX-inhibitors. While COX-inhibitors have shown some therapeutic potential, they prevent the synthesis of a number of prostaglandins, of which only some are harmful, and some have beneficial effects. There is thus a need in the art for methods for treating uterine pathologies by specifically inhibiting the action of specified prostaglandins.

A first aspect of the invention provides a method of treating or preventing a pathological condition of the uterus in a female individual, the method comprising administering to the individual at least one agent that prevents  $\text{PGF}_{2\alpha}$  having its effect on the FP receptor.

The pathological condition of the uterus treatable by the methods of the invention may be any pathological condition wherein  $\text{PGF}_{2\alpha}$  (FP) receptors are upregulated in proliferating tissue. Typically, the pathological condition of the uterus is any one of uterine carcinoma, an endometrial pathological condition such as endometriosis including adenomyosis, or a myometrial pathological condition such as fibroids (leiomyomas) or leiomyosarcomas which are fibroids which have become malignant. Thus, typically, the uterine pathological

condition is one which is associated with abnormal growth of cells of the myometrium or endometrium. Endometriosis is the ectopic implantation and growth of endometrium and can therefore be considered as abnormal growth of cells of the endometrium. Adenomyosis is a form of endometriosis where the  
5 ectopic endometrium is implanted in the myometrium.

The invention includes the treatment of any of uterine carcinoma, an endometrial pathological condition such as endometriosis, or a myometrial pathological condition such as fibroids, with at least one agent that prevents  $\text{PGF}_{2\alpha}$  having its effect on the FP receptor.

10 Uterine pathological conditions treatable by the methods of the invention do not include premature delivery of a foetus or dysmenorrhea.

It is particularly preferred if the method of the invention is used to treat endometrial carcinoma.

Certain uterine pathological conditions are believed to be associated with  
15 overproliferation of the epithelium.

Typically, the agent is one which prevents or disrupts  $\text{PGF}_{2\alpha}$ -mediated signalling of the FP receptor.

Preferably, an agent that prevents  $\text{PGF}_{2\alpha}$  having its effect on the FP receptor prevents or reduces the binding of  $\text{PGF}_{2\alpha}$  to the FP receptor. Alternatively or  
20 additionally, the agent may affect the interaction between  $\text{PGF}_{2\alpha}$  and the FP receptor, or the interaction between the FP receptor and the associated  $G_{\alpha q}$  protein, thus inhibiting or disrupting the  $\text{PGF}_{2\alpha}$ -FP mediated signal transduction pathway.

In one preferred embodiment, the agent that prevents  $\text{PGF}_{2\alpha}$  having its effect on  
25 the FP receptor may be an antagonist of the FP receptor. FP receptor antagonists are typically molecules which bind to the FP receptor, compete with the binding



of the natural ligand  $\text{PGF}_{2\alpha}$  and inhibit or disrupt the  $\text{PGF}_{2\alpha}$ -FP mediated signal transduction pathway.

In one preferred embodiment, preventing  $\text{PGF}_{2\alpha}$  having its effect on the FP receptor includes occupying the  $\text{PGF}_{2\alpha}$  binding site on the prostaglandin  
5 receptor, such that the natural ligand ( $\text{PGF}_{2\alpha}$ ) is prevented from binding in a mode that would result in its normal mode of signalling *via*  $\text{Gq/Gq}_\Pi$  through inositolphosphate and subsequent mobilisation of intracellular calcium.

Alternatively, the receptor antagonist may be a molecule which binds to the FP receptor without preventing  $\text{PGF}_{2\alpha}$  binding thereto, but which disrupts the  
10 interaction between  $\text{PGF}_{2\alpha}$  and the FP receptor, thus inhibiting or disrupting  $\text{PGF}_{2\alpha}$ -FP mediated signal transduction pathway.

Further alternatively, the FP receptor antagonist may be a molecule which binds to the FP receptor and which disrupts the interaction between the FP receptor and the associated  $\text{G}_{\alpha q}$  protein, thus inhibiting or disrupting FP mediated signal  
15 transduction pathway.

In an alternative preferred embodiment, the agent may be an antagonist of  $\text{PGF}_{2\alpha}$ .  $\text{PGF}_{2\alpha}$  antagonists are typically molecules which bind to  $\text{PGF}_{2\alpha}$  and prevent or reduce  $\text{PGF}_{2\alpha}$  binding to its receptor, which inhibits or disrupts the  $\text{PGF}_{2\alpha}$ -FP mediated signal transduction pathway. This is the 'soluble receptor'  
20 approach in which typically either a part of the receptor or an antibody binds to  $\text{PGF}_{2\alpha}$ .

Alternatively, the  $\text{PGF}_{2\alpha}$  antagonist may be a molecule which binds to  $\text{PGF}_{2\alpha}$  without preventing or reducing the binding of  $\text{PGF}_{2\alpha}$  to the FP receptor, but which disrupts the interaction between  $\text{PGF}_{2\alpha}$  and the FP receptor such that the  
25  $\text{PGF}_{2\alpha}$ -FP mediated signal transduction pathway is inhibited or disrupted. This could be a molecule which binds in a covalent fashion to  $\text{PGF}_{2\alpha}$  and has no effect on binding potency but effects the G-protein/IP/ $\text{Ca}^{2+}$  mechanisms.

In one preferred embodiment, the agent that prevents  $\text{PGF}_{2\alpha}$  having its effect on the FP receptor comprises an antagonist of the FP receptor, which may be any FP receptor antagonist that is suitable to be administered to a patient. The receptor antagonists are typically selective to the particular receptor and preferably have an equal or higher binding affinity to the FP receptor than does  $\text{PGF}_{2\alpha}$ . Although antagonists with a higher affinity for the receptor than the natural ligand are preferred, antagonists with a lower affinity may also be used, but it may be necessary to use these at higher concentrations. Preferably, the antagonists bind reversibly to the FP receptor. Preferably, antagonists are selective for a particular receptor and do not affect other receptors; thus, typically, an FP receptor antagonist binds the FP receptor but does not substantially bind any other receptor.

The peptides listed in Table 1 are reported to be antagonists of the FP receptor that disrupt the interaction between the FP receptor and the associated  $G_{\alpha q}$  protein (WO 99/32640 and WO 00/17438). The amino acids are indicated according to the standard IUPAC single letter convention, and X is cyclohexyl alanine. Lower case letters indicate L-amino acids and capital letters indicate D-amino acids. All of the disclosure in WO 99/32640 and WO 00/17438 relating to specific peptides as FP receptor antagonists, is hereby incorporated herein by reference.

**Table 1**

PCP-1	RVKFKSQQHRQGRSHHLEM
PCP-2	RKAVLKNLYKLASQCCGVHVLSLHTWELSSIKNSLKVAAISESP VAEKSAST
PCP-3	CLSEEAKEARRINDEIERQLRRDKRDARRE-NH <sub>2</sub>
PCP-4	KDTILQLNLKEYNLV-NH <sub>2</sub>
PCP-8	ilghrdyk
PCP-10	wedrfyll
PCP-13	ILGHRDYK

PCP-14	YQDRFYLL
PCP-13.7	ILAHRDYK
PCP-13.8	ILaHRDYK
PCP-13.11	ILGFRDYK
PCP-13.13	ILGHKDYK
PCP-13.14	ILGHRNYK
PCP-13.18	ILGHQDYK
PCP-13.20	ILGHRDY-amide
PCP-13.21	ILGHRDYK-amide
PCP-13.22	ILGWRDYK
PCP-13.24	ILGXRDYK
PCP-15	SNVLCSIF

When the antagonist comprises a peptide, such as those mentioned in Table 1, the antagonist may also comprise protein fusions or peptidomimetics thereof.

PGF<sub>2α</sub> dimethyl amide, obtained from Cayman Chemical, Ann Arbor, MI, USA was reported to be a PGF<sub>2α</sub> receptor antagonist (Arnould *et al.*, (2001) *Am. J. Pathol.*, 159(1): 345-357).

AL-8810 ((5Z, 13E)-(9S,11S,15R)-9,15-dihydroxy-11-fluoro-15-(2-indanyl)-16, 17, 18, 19, 20-pentanoic acid) obtained from Alcon Research was reported to be a weak partial agonist of the PGF<sub>2α</sub> receptor and a highly selective antagonist of the PGF<sub>2α</sub> receptor. AL-8810 was reported not to significantly inhibit functional responses of prostaglandin receptors TP, DP, EP2 or EP4 at high 10 μM concentration (Griffin *et al.*, (1999) *J. Pharmacol. Exp. Ther.*, 260(3): 1278-1284).

AL-3138 (11-deoxy-16-fluoro PGF<sub>2α</sub>) was reported to be a weak partial agonist of the PGF<sub>2α</sub> receptor, and also a highly selective antagonist of the PGF<sub>2α</sub> receptor (Sharif *et al.*, (2000) *J. Pharm. Pharmacol.*, 52(12): 1529-1539).

Phloretin was reported to be a  $\text{PGF}_{2\alpha}$  receptor antagonist (Kitanaka *et al* (1993) *J. Neurochem.* 60(2): 704-708).

The sulfonylurea glibenclamide was reported to be a  $\text{PGF}_{2\alpha}$  receptor antagonist (Delaey and Van de Voorde (1995), *Eur. J. Pharmacol.* 280(2): 179-184). The  
5 sulfonylureas tolbutamide and tolazamide were reported to be very weak antagonists of the FP receptor. (Sharif *et al* (2000) *J. Pharm. Pharmacol.*, 52(12): 1529-1539).

$\text{PGF}_{2\alpha}$  dimethyl amine was reported to be a  $\text{PGF}_{2\alpha}$  receptor antagonist (Stinger *et al* (1992), *J. Pharmacol. Exp. Ther.*, 220: 521-525).

10 (E)-5-[[[(3-pyridinyl)[3-(trifluoromethyl) phenyl]methylen]amino]oxy]pentanoic acid, also known as ridogrel, obtained from Janssen Pharmaceutica, was reported to be a  $\text{PGF}_{2\alpha}$  receptor antagonist (Jannsens *et al.*, (1990), *Thrombosis and Haemostasis*, 64(1): 91-96).

The compound PHG113 was reported to be a selective  $\text{PGF}_{2\alpha}$  receptor  
15 antagonist (Quiniou *et al.*, (2001) *Pediatric Research*, 49(2): 452A.

EP-128479 describes pyrazolyl-methyl-ergoline derivatives which are reported to be  $\text{PGF}_{2\alpha}$  receptor antagonists. All the disclosure in EP-128479 relating to pyrazolyl-methyl-ergoline derivatives as  $\text{PGF}_{2\alpha}$  receptor inhibitors, is hereby incorporated herein by reference.

20 In a further preferred embodiment of the invention, the agent that prevents  $\text{PGF}_{2\alpha}$  having its effect on the FP receptor may be an antagonist of  $\text{PGF}_{2\alpha}$ , which may be any  $\text{PGF}_{2\alpha}$  antagonist that is suitable to be administered to the patient. The  $\text{PGF}_{2\alpha}$  antagonists are preferably selective to  $\text{PGF}_{2\alpha}$  and typically have a higher binding affinity for  $\text{PGF}_{2\alpha}$  than for other molecules. Although  
25 antagonists with a higher affinity for  $\text{PGF}_{2\alpha}$  than other molecules are preferred, antagonists with a lower affinity may also be used, but it may be necessary to

use these at higher concentrations. Preferably, the  $\text{PGF}_{2\alpha}$  antagonists bind reversibly to  $\text{PGF}_{2\alpha}$ .

$\text{PGF}_{2\alpha}$  antagonists include anti- $\text{PGF}_{2\alpha}$  antibodies such as rabbit polyclonal anti- $\text{PGF}_{2\alpha}$  antibodies from Oxford Biomedical Research, Inc., Oxford, UK (Arnould  
5 *et al.*, *Am. J. Pathol.* 2001 159(1): 345-357). Arnould *et al* state that, according to the manufacturer, the specificity of the antibody is very high and the cross-reactivity with other prostanoid derivatives is <1%.

JP 04077480; JP 08176134; JP 01199958; JP 01050818; and JP 63083081 each describe phthalide derivatives that are reported to be  $\text{PGF}_{2\alpha}$  inhibitors. All the  
10 disclosure in JP 04077480; JP 08176134; JP 01199958; JP 01050818; and JP 63083081 relating to phthalide derivatives as  $\text{PGF}_{2\alpha}$  inhibitors, is hereby incorporated herein by reference.

WO 91/13875 describes (iso) quinoline sulphonamide compounds which are reported to be  $\text{PGF}_{2\alpha}$  inhibitors. All the disclosure in WO 91/13875 relating to  
15 (iso) quinoline sulphonamide compounds as  $\text{PGF}_{2\alpha}$  inhibitors, is hereby incorporated herein by reference.

Some of the compounds reported as being inhibitors or antagonists of  $\text{PGF}_{2\alpha}$  may, in fact, be antagonists of the  $\text{PGF}_{2\alpha}$  (FP) receptor, as used and defined herein. References to such compounds as inhibitors or antagonists of  $\text{PGF}_{2\alpha}$   
20 should therefore be considered as references to FP receptor antagonists.

As used herein, the term 'antagonist' covers all types of antagonism. GPCRs such as prostaglandin receptors are known to show inverse agonism which has the outcome of blocking a desired response. Thus a suitable FP antagonist for use in the present invention may be identified by measuring the binding of a  
25 radio-labelled FP agonist to  $\text{PGF}_{2\alpha}$  with or without the purported antagonist. Secondly, FP antagonists may be identified in a functional assay *eg* by showing that the effect of an FP agonist on  $\text{Ca}^{2+}$  levels is modified in the presence of the

antagonist. Thirdly FP antagonists may be identified by inhibition of epithelial cell growth in cell culture.

We have previously found that PGES expression and PGE<sub>2</sub> synthesis are also up-regulated in adenocarcinoma of the human uterus. Expression of these factors was localised to the neoplastic epithelial cells of the uterine carcinoma tissues as well as the endothelial cells of the microvasculature. This is associated with an overexpression and signalling of the EP2 and EP4 receptors in the carcinoma tissue.

Thus in a further embodiment of the present invention, in addition to the at least one agent that prevents PGF<sub>2α</sub> having its effect on the FP receptor, the individual is also administered an inhibitor of PGES and/or an antagonist of EP2 or of EP4.

In one embodiment of the invention, the individual is administered an inhibitor of PGES. It has been reported by Thorén & Jakobsson (2000) *Eur. J Biochem.* 267, 6428-6434 (incorporated herein by reference) that NS-398, sulindac sulphide and leukotriene C<sub>4</sub> inhibit PGES activity with IC<sub>50</sub> values of 20μM, 80μM and 5μM, respectively.

In a still further embodiment of the invention, the individual is administered an antagonist of an EP2 receptor or an antagonist of an EP4 receptor.

The prostaglandin EP2 receptor antagonist may be any suitable EP2 receptor antagonist. Similarly, the prostaglandin EP4 receptor antagonist may be any suitable EP4 receptor antagonist. By "suitable" we mean that the antagonist is one which may be administered to a patient. The receptor antagonists are molecules which bind to their respective receptors, compete with the natural ligand (PGE<sub>2</sub>) and inhibit the initiation of the specific receptor-mediated signal transduction pathways. The receptor antagonists are typically selective to the particular receptor and typically have a higher binding affinity to the receptor than the natural ligand. Although antagonists with a higher affinity for the receptor than the natural ligand are preferred, antagonists with a lower affinity

may also be used, but it may be necessary to use these at higher concentrations. Preferably, the antagonists bind reversibly to their cognate receptor. Typically, antagonists are selective for a particular receptor and do not affect the other receptor; thus, typically, an EP2 receptor antagonist binds the EP2 receptor but  
5 does not substantially bind the EP4 receptor, whereas an EP4 receptor antagonist binds the EP4 receptor but does not substantially bind the EP2 receptor. Preferably, the EP2 or EP4 receptor antagonist is selective for the particular receptor subtype. By this is meant that the antagonist has a binding affinity for the particular receptor subtype which is at least ten-fold higher than for at least  
10 one of the other EP receptor subtypes. Thus, selective EP4 receptor antagonists have at least a ten-fold higher affinity for the EP4 receptor than any of the EP1, EP2 or EP3 receptor subtypes.

It is particularly preferred that the EP2 or EP4 receptor antagonist is selective for its cognate receptor.

15 EP2 receptor antagonists include AH6809 (Pelletier *et al* (2001) *Br. J. Pharmacol.* 132, 999-1008).

EP4 receptor antagonists include AH23848B (developed by Glaxo) and AH22921X (Pelletier *et al* (2001) *Br. J. Pharmacol.* 132, 999-1008. The chemical name for AH23848B is ([1alpha(z), 2beta5alpha]-(+/-)-7-[5-[[[(1,1'-  
20 biphenyl)-4-yl]methoxy]-2-(4-morpholinyl)-3-oxo-cyclopentyl]-4-heptenoic acid) (see Hillock & Crankshaw (1999) *Eur. J. Pharmacol.* 28, 99-108). EP4RA (Li (2000) *Endocrinology* 141, 2054-61) is an EP(4) -selective ligand (Machwate *et al* (2001) *Mol. Pharmacol.* 60: 36-41). The omega-substituted prostaglandin E derivatives described in WO 00/15608 (EP 1 114 816) (Ono  
25 Pharm Co Ltd) bind EP4 receptors selectively and may be EP4 receptor antagonists.

Peptides described in WO 01/42281 (Hopital Sainte-Justine) eg: IFTSYLECL, IFASYECL, IFTSAECL, IFTSYEAL, ILASYECL, IFTSTDCL, TSYEAL (with

4-biphenyl alanine), TSYEAL (with homophenyl alanine) are also described as EP4 receptor antagonists, as are some of the compounds described in WO 00/18744 (Fujisawa Pharm Co Ltd). The 5-thia-prostaglandin E derivatives described in WO 00/03980 (EP 1 097 922) (Ono Pharm Co Ltd) may be EP4  
5 receptor antagonists.

EP4 receptor antagonists are also described in WO 01/10426 (Glaxo), WO 00/21532 (Merck) and GB 2 330 307 (Glaxo).

WO 00/21532 describes the following as EP4 receptor antagonists:

5-butyl-2,4-dihydro-4-[[2'-[N-(3-chloro-2-  
10 thiophenecarbonyl)sulfamoyl]biphenyl-4-yl]methyl]-2-{2-(trifluoromethyl)phenyl}-1,2,4-triazol-3-one potassium salt;

5-butyl-2,4-dihydro-4-[[2'-[N-(2-methyl-3-furoyl)sulfamoyl]biphenyl-4-yl]methyl]-2-{2-(trifluoromethyl)phenyl}-1,2,4-triazol-3-one;

5-butyl-2,4-dihydro-4-[[2'-[N-(3-methyl-2-  
15 thiophenecarbonyl)sulfamoyl]biphenyl-4-yl]methyl]-2-{2-(trifluoromethyl)phenyl}-1,2,4-triazol-3-one;

5-butyl-2,4-dihydro-4-[[2'-[N-(2-thiophenecarbonyl)sulfamoyl]biphenyl-4-yl]methyl]-2-{2-(trifluoromethyl)phenyl}-1,2,4-triazol-3-one;

5-butyl-2,4-dihydro-4-[[2'-[N-[2-(methypyrrole)carbonyl]sulfamoyl]biphenyl-4-yl]methyl]-2-{2-(trifluoromethyl)phenyl}-1,2,4-triazol-3-one.  
20

GB 2 330 307 describes [1 $\alpha$ (Z), 2 $\beta$ ,5 $\alpha$ ]( $\pm$ )-7-[5-[[1,1'-biphenyl]-4-yl]methoxy]-2-(4-morpholinyl)-3-oxocyclopentyl]-4-heptenoic acid and [1R[1 $\alpha$ (z),2 $\beta$ ,5 $\alpha$ ]](-)-7-[5-[[1,1'-biphenyl]-4-yl]methoxy]-2-(4-morpholinyl)-3-oxocyclopentyl]-4-heptenoic acid.



WO 00/18405 (Pharmagene) describes the EP4 receptor antagonists AH22921 and AH23848 (which are also described in GB 2 028 805 and US 4, 342, 756). WO 01/72302 (Pharmagene) describes further EP4 receptor antagonists, for example those described by reference to, and included in the general formula (I) shown on page 8 *et seq.*

Typically, when an inhibitor of PGES and/or an antagonist of EP2 or of EP4 is administered to a patient in addition to the at least one agent that prevents  $\text{PGF}_{2\alpha}$  having its effect on the FP receptor, the dose of each compound is the same as would be administered individually without reference to the other compound. Alternatively, lower doses may be administered.

All of the patents and other documents referred to herein, and in particular those describing antagonists or inhibitors of FP receptors,  $\text{PGF}_{2\alpha}$ , EP2 or EP4 and PGES, are incorporated herein, in their entirety, by reference.

It will be appreciated that one or more agents that prevents  $\text{PGF}_{2\alpha}$  having its effect on the FP receptor may be administered to the patient. These may all be considered "treatment agents" of the invention. It will also be appreciated that when more than one treatment agent is administered to the patient, they may be administered sequentially or in combination.

The treatment agent(s) are administered in an effective amount to combat the undesired pathological condition of the uterus. Thus, the treatment agents may be used to alleviate symptoms (ie are used palliatively), or may be used to treat the condition, or may be used prophylactically to prevent the condition. The treatment agent may be administered by any suitable route, and in any suitable form.

Typically, the aforementioned treatment agents for use in the invention are administered in a quantity and frequency such that an effective dose is delivered

to at least 90% of the FP receptors ( $ED_{90}$ ). The potency of the molecule would dictate the dose, as would the formulation and route of administration.

The aforementioned treatment agents for use in the invention or a formulation thereof may be administered by any conventional method including oral and  
5 parenteral (eg subcutaneous or intramuscular) injection. The treatment may consist of a single dose or a plurality of doses over a period of time. The dose to be administered is determined upon consideration of age, body weight, mode of administration, duration of the treatment and pharmacokinetic and toxicological  
10 properties of the treatment agent or agents. The treatment agents are administered at a dose (or in multiple doses) which produces a beneficial therapeutic effect in the patient. Typically, the treatment agents are administered at a dose the same as or similar to that used when the treatment agent is used for another medical indication. In any event, the dose suitable for treatment of a patient may be determined by the physician.

15 Whilst it is possible for a treatment agent of the invention to be administered alone or in combination with other said treatment agents, it is preferable to present it or them as a pharmaceutical formulation, together with one or more acceptable carriers. The carrier(s) must be "acceptable" in the sense of being compatible with the treatment agent of the invention and not deleterious to the  
20 recipients thereof. Typically, the carriers will be water or saline which will be sterile and pyrogen free.

The formulations may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. Such methods include the step of bringing into association the treatment agent or agents with the  
25 carrier which constitutes one or more accessory ingredients. In general the formulations are prepared by uniformly and intimately bringing into association the active ingredient (ie treatment agent or agents) with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product.

Formulations in accordance with the present invention suitable for oral administration may be presented as discrete units such as capsules, cachets or tablets, each containing a predetermined amount of the active ingredient; as a powder or granules; as a solution or a suspension in an aqueous liquid or a non-  
5 aqueous liquid; or as an oil-in-water liquid emulsion or a water-in-oil liquid emulsion. The active ingredient may also be presented as a bolus, electuary or paste.

A tablet may be made by compression or moulding, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing in a  
10 suitable machine the active ingredient in a free-flowing form such as a powder or granules, optionally mixed with a binder (eg povidone, gelatin, hydroxypropylmethyl cellulose), lubricant, inert diluent, preservative, disintegrant (eg sodium starch glycolate, cross-linked povidone, cross-linked sodium carboxymethyl cellulose), surface-active or dispersing agent. Moulded tablets may  
15 be made by moulding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent. The tablets may optionally be coated or scored and may be formulated so as to provide slow or controlled release of the active ingredient therein using, for example, hydroxypropylmethylcellulose in varying proportions to provide desired release profile.

20 Formulations suitable for topical administration in the mouth include lozenges comprising the active ingredient in a flavoured basis, usually sucrose and acacia or tragacanth; pastilles comprising the active ingredient in an inert basis such as gelatin and glycerin, or sucrose and acacia; and mouth-washes comprising the active ingredient in a suitable liquid carrier. Buccal administration is also  
25 preferred.

Formulations suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which

may include suspending agents and thickening agents. The formulations may be presented in unit-dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in a freeze-dried (lyophilised) condition requiring only the addition of the sterile liquid carrier, for example water for injections, immediately prior to use. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets of the kind previously described.

Preferred unit dosage formulations are those containing a daily dose or unit, daily sub-dose or an appropriate fraction thereof, of an active ingredient.

It should be understood that in addition to the ingredients particularly mentioned above the formulations of this invention may include other agents conventional in the art having regard to the type of formulation in question, for example those suitable for oral administration may include flavouring agents.

Certain of the treatment agents are proteins or peptides. Proteins and peptides may be delivered using an injectable sustained-release drug delivery system. These are designed specifically to reduce the frequency of injections. An example of such a system is Nutropin Depot which encapsulates recombinant human growth hormone (rhGH) in biodegradable microspheres that, once injected, release rhGH slowly over a sustained period.

The protein and peptide can be administered by a surgically implanted device that releases the drug directly to the required site. For example, Vitrasert releases ganciclovir directly into the eye to treat CMV retinitis. The direct application of this toxic agent to the site of disease achieves effective therapy without the drug's significant systemic side-effects.

Electroporation therapy (EPT) systems can also be employed for the administration of proteins and peptides. A device which delivers a pulsed electric field to cells increases the permeability of the cell membranes to the drug, resulting in a significant enhancement of intracellular drug delivery.

Proteins and peptides can be delivered by electroincorporation (EI). EI occurs when small particles of up to 30 microns in diameter on the surface of the skin experience electrical pulses identical or similar to those used in electroporation. In EI, these particles are driven through the stratum corneum and into deeper layers of the skin. The particles can be loaded or coated with drugs or genes or can simply act as "bullets" that generate pores in the skin through which the drugs can enter.

An alternative method of protein and peptide delivery is the ReGel injectable system that is thermo-sensitive. Below body temperature, ReGel is an injectable liquid while at body temperature it immediately forms a gel reservoir that slowly erodes and dissolves into known, safe, biodegradable polymers. The treatment agent is delivered over time as the biopolymers dissolve.

Protein and peptide pharmaceuticals can also be delivered orally. The process employs a natural process for oral uptake of vitamin B<sub>12</sub> in the body to co-deliver proteins and peptides. By riding the vitamin B<sub>12</sub> uptake system, the protein or peptide can move through the intestinal wall. Complexes are synthesised between vitamin B<sub>12</sub> analogues and the drug that retain both significant affinity for intrinsic factor (IF) in the vitamin B<sub>12</sub> portion of the complex and significant bioactivity of the drug portion of the complex.

Proteins and polypeptides can be introduced to cells by "Trojan peptides". These are a class of polypeptides called penetratins which have translocating properties and are capable of carrying hydrophilic compounds across the plasma membrane. This system allows direct targeting of oligopeptides to the cytoplasm and nucleus, and may be non-cell type specific and highly efficient. See Derossi *et al* (1998), *Trends Cell Biol* 8, 84-87.

The treatment agents or formulations may also be administered transdermally, eg as a patch, gel, lotion, cream or oil.

It is preferred if the treatment agent (or agents) is administered orally.

It is further preferred if the treatment agent (or agents) is administered to the female reproductive system. For example, the treatment agent or agents may suitably be administered intravaginally using, for example, a gel or cream or vaginal ring or tampon. The treatment agent may also advantageously be administered by intrauterine delivery, for example using methods well known in the art such as an intrauterine device.

Typically, the gel or cream is one which is formulated for administration to the vagina. It may be oil based or water based. Typically, the treatment agent (or agents) is present in the cream or gel in a sufficient concentration so that an effective amount is administered in a single (or in repeated) application.

Typically, the vaginal ring comprises a polymer which formed into a "doughnut" shape which fits within the vagina. The treatment agent (or agents) is present within the polymer, typically as a core, which may dissipate through the polymer and into the vagina and/or cervix in a controlled fashion. Vaginal rings are known in the art.

Typically, the tampon is impregnated with the treatment agent (or agents) and that a sufficient amount of the treatment agent (or agents) is present in the tampon.

Typically, the intrauterine device is for placing in the uterus over extended periods of time, such as between one and five years. Typically, the intrauterine device comprises a plastic frame, often in the shape of a "T" and contains sufficient of the treatment agent(s) to be released over the period of use. The agent is generally present within or encompassed by a slow-release polymer which forms part of the device, such as in the form of a "sausage" of agent which wraps around the long arm of the "T" which is typically covered with a controlled-release membrane. Intrauterine devices are known in the art.

The individual to be treated may be any female individual who would benefit from such treatment. Typically and preferably the individual to be treated is a

human female. However, the methods of the invention may be used to treat female mammals, such as the females of the following species: cows, horses, pigs, sheep, cats and dogs. Thus, the methods have uses in both human and veterinary medicine.

- 5 A second aspect of the invention provides use of at least one agent that prevents  $\text{PGF}_{2\alpha}$  having its effect on the FP receptor, in the manufacture of a medicament for treating or preventing a pathological condition of the uterus in a female individual.

- A third aspect of the invention provides use of at least one agent that prevents  
10  $\text{PGF}_{2\alpha}$  having its effect on the FP receptor, in the manufacture of a medicament for treating or preventing a pathological condition of the uterus in a female individual, wherein the individual is administered an inhibitor of PGES and/or an antagonist of EP2 or EP4. Typically the female is administered the inhibitor of PGES and/or antagonist of EP2 or EP4 at the same time as the medicament,  
15 although the female may have been (or will be) administered the inhibitor of PGES and/or antagonist of EP2 or EP4 before (or after) receiving the medicament containing the at least one agent that prevents  $\text{PGF}_{2\alpha}$  having its effect on the FP receptor.

- A fourth of the invention provides use of an inhibitor of PGES and/or an  
20 antagonist of EP2 or EP4 in the manufacture of a medicament for treating or preventing a pathological condition of the uterus in a female individual, wherein the individual is administered at least one agent that prevents  $\text{PGF}_{2\alpha}$  having its effect on the FP receptor. In this case, typically the female is administered the at least one agent that prevents  $\text{PGF}_{2\alpha}$  having its effect on the FP receptor at the  
25 same time as the medicament, although the female may have been (or will be) administered the at least one agent that prevents  $\text{PGF}_{2\alpha}$  having its effect on the FP receptor before (or after) receiving the medicament containing the inhibitor of PGES and/or antagonist of EP2 or EP4.

In a fifth aspect of the invention, a combination of at least one agent that prevents  $\text{PGF}_{2\alpha}$  having its effect on the FP receptor, and an inhibitor of PGES and/or an antagonist of EP2 or EP4, is used in the manufacture of a medicament for treating or preventing a pathological condition of the uterus in a female individual.

A sixth aspect of the invention provides a pharmaceutical composition comprising at least one agent that prevents  $\text{PGF}_{2\alpha}$  having its effect on the FP receptor, for treating or preventing a pathological condition of the uterus.

Optionally, the pharmaceutical composition may also comprise an inhibitor of PGES and/or an antagonist of EP2 or EP4.

Preferably, in the second, third, fourth, fifth and sixth aspects of the invention, the agent that prevents  $\text{PGF}_{2\alpha}$  having its effect on the FP receptor is as defined with respect to the first aspect of the invention.

Preferably, in the second, third, fourth, fifth and sixth aspects of the invention, the pathological condition of the uterus is as defined with respect to the first aspect of the invention.

Preferably, the pathological condition of the uterus is uterine carcinoma or an endometrial or myometrial pathological condition.

It is believed that there has been no previous description of a composition comprising at least one agent that prevents  $\text{PGF}_{2\alpha}$  having its effect on the FP receptor, and an inhibitor of PGES and/or an antagonist of EP2 or EP4. Furthermore, it is believed that there has been no previous suggestion that such a composition could be used to treat any medical condition.

Therefore, in a further aspect, the invention includes a composition comprising at least one agent that prevents  $\text{PGF}_{2\alpha}$  having its effect on the FP receptor, and an inhibitor of PGES and/or an antagonist of EP2 or EP4.



In a yet further aspect, the invention includes a pharmaceutical composition comprising at least one agent that prevents  $\text{PGF}_{2\alpha}$  having its effect on the FP receptor, and an inhibitor of PGES and/or an antagonist of EP2 or EP4, for use in medicine.

- 5 The invention will now be described in more detail by reference to the following Figures and Examples.

**Figure 1**

*In situ* hybridisation for FP receptor in (a-f) normal human endometrium, and in (g-i) adenocarcinoma tissues.

10 **Figure 2**

Quantitative RT-PCR expression of FP receptor in a) normal human endometrium and b) adenocarcinoma tissues ( $p < 0.05$ ). In a), EP is early proliferative phase, MP/LP is mid/late proliferative phase, ES is early secretory phase and LS is late secretory phase. In b), "Cycle" is an average of EP, MP/LP,  
15 ES and LS from a).

**Figure 3**

IP3 production in human endometrium.

**Figure 4**

ERK phosphorylation in Ishikawa cells.  $\text{PGF}_{2\alpha}$  100nM was incubated for 10 and  
20 30 min. U73122 2 $\mu\text{M}$  was pre-incubated for 60 min before treatment with  $\text{PGF}_{2\alpha}$ .

**Figure 5**

Proliferation in Ishikawa cells following  $\text{PGF}_{2\alpha}$ . Cells were treated overnight with  $\text{PGF}_{2\alpha}$ . All inhibitors were added for 60 min before the addition of  $\text{PGF}_{2\alpha}$   
25 ( $n \geq 4$ ;  $p < 0.05$ ).

**Example 1: Prostaglandin (PG)  $F_{2\alpha}$  receptor expression and localisation in human endometrium and endometrial adenocarcinoma: role of  $PGF_{2\alpha}$  in epithelial cell proliferation**

*Summary*

- 5  $PGF_{2\alpha}$  is one of the prostaglandins generated by human endometrium and can be measured in menstrual fluid and from endometrial explants cultured *in vitro*.  $PGF_{2\alpha}$  production is stimulated by oestrogen, which induces an up-regulation of COX expression, and inhibited by progesterone, which decreases COX expression and increases PGDH expression. Increased COX expression has
- 10 been demonstrated in a number of different cancers and over-expression in rat intestinal epithelial (RIE) cells induces an altered cell type with increased proliferation and invasiveness *in vivo*. The aims of this study were to identify the target cells for  $PGF_{2\alpha}$  in human endometrium and endometrial adenocarcinoma and quantify FP receptor expression in these tissues. The role
- 15 of  $PGF_{2\alpha}$  in epithelial cell proliferation, and the specific signalling pathways involved, was then determined in an endometrial adenocarcinoma cell line (Ishikawa). We observed a significantly increased expression of FP mRNA in mid- to late-proliferative tissue that was further increased in endometrial adenocarcinomas. Localisation of FP mRNA was identified in epithelial cells
- 20 from only mid- and late-proliferative tissue samples. In uterine adenocarcinoma tissue, FP expression was consistently localised in epithelial cells and was independent of differentiation stage. Negligible FP mRNA expression was seen in adjacent stromal cells. Inositol mobilisation in response to  $PGF_{2\alpha}$  was determined in normal endometrium and endometrial adenocarcinoma and was
- 25 significantly increased in all samples following  $PGF_{2\alpha}$ , however, no additional inositol mobilisation was found in adenocarcinoma samples. In Ishikawa cells,  $PGF_{2\alpha}$  also induced inositol mobilisation and produced a concentration-dependent increase in cell proliferation that was inhibited PLC-dependent but not affected by either p38 or p42/p44 MAPK inhibitors. These results

demonstrate that proliferating endometrial epithelial cells are responsive to  $\text{PGF}_{2\alpha}$  and indicate a role for  $\text{PGF}_{2\alpha}$  in endometrial epithelial cell proliferation.

### *Introduction*

Prostaglandin (PG)  $\text{F}_{2\alpha}$  is a prostanoid belonging to the eicosanoid family of biologically active lipid (1). Other members of this prostanoid family include PGD<sub>2</sub>, PGE<sub>2</sub>, prostacyclin (PGI<sub>2</sub>) and thromboxane A<sub>2</sub> (TxA<sub>2</sub>) that are all synthesised from arachidonic acid by a combination of cyclooxygenase (COX) and specific synthase enzymes (2). To-date, there are two identified isoforms of the COX enzyme; constitutively expressed COX-1 that generates PG for normal physiological function and COX-2, an early response gene whose expression can be rapidly induced (3). COX metabolises arachidonic acid to the unstable intermediate PGH<sub>2</sub> and specific synthase enzymes then convert PGH<sub>2</sub> to the PG molecules (4-8). The PG synthase enzymes are named according to the prostaglandin they produce such that  $\text{PGF}_{2\alpha}$  is a metabolite of prostaglandin-F-synthase. Once synthesised PG mediate their actions via seven-transmembrane G-protein coupled receptors (GPCR) specific to each prostanoid.  $\text{PGF}_{2\alpha}$  receptor (FP) has been cloned in humans and transduces its response via the G-protein G<sub>q</sub>, PLC activation and generation of inositol-trisphosphate that in turn mobilises intracellular  $\text{Ca}^{2+}$ .

COX enzymes and PG have recently been demonstrated to regulate epithelial cell growth and angiogenesis. In rat intestinal epithelial cells, COX-2 expression and PGE<sub>2</sub> synthesis are associated with increased cellular proliferation and resistance to apoptosis (9,10). The same group also showed that expression of COX-2 in epithelial cells enhances the expression of angiogenic factors that act in a paracrine manner to induce endothelial cell migration and microvascular tube formation (9). In human endometrium, COX-2 enzyme expression is maximal during the proliferative phase and is localised to epithelial and perivascular cells (10-14).

We have demonstrated over-expression and increased signalling of PGE2 and EP receptors in proliferating endometrium and human adenocarcinoma. These findings substantiate a role for PGE2 in normal endometrial function and also implicate COX in neoplastic transformation of epithelial cells.

- 5 PGF<sub>2α</sub> is also a major metabolite of COX in human endometrium and as well as being present in menstrual fluid is released by human endometrial explants in culture (15). However, due to the potent luteolytic activity of PGF<sub>2α</sub> and the demonstrated increase in myometrial contractility following PGF<sub>2α</sub>, most studies have focused on FP receptor expression and regulation in the ovary. FP receptor  
10 expression and the role of PGF<sub>2α</sub> within the functionalis layer of human endometrium have not been fully examined.

Original studies identified in separated bovine endometrial cells cultured *in vitro*, that epithelial cells preferentially release PGF<sub>2α</sub> in contrast to stromal cells that secrete predominately PGE2 (16). Moreover, studies measuring FP mRNA  
15 in non-primate species demonstrated increased FP receptor expression with oestrogen where as progesterone decreased FP receptor expression when animal were ovariectomised (17-19).

The aims of this study were to localise and quantify FP receptor expression both in human endometrium and in differing grades of human uterine  
20 adenocarcinoma to identify the PGF<sub>2α</sub>-responsive cells. Mobilisation of inositol phosphates and phosphorylation of the MAPK extracellular-regulated kinase (ERK) were used to determine the presence of functional FP receptors and BrdU incorporation in Ishikawa cells as an in-vitro proliferation assay. The data from this study demonstrate epithelial expression of FP in only proliferating tissue  
25 with substantially increased FP mRNA and clear epithelial cell localisation in endometrial adenocarcinomas. Moreover, PGF<sub>2α</sub> treatment of Ishikawa cells caused inositol mobilisation, ERK phosphorylation and concentration-dependent increases in cell proliferation.

The data reported herein is the first report of FP expression in human endometrium and demonstrates a potential role of  $\text{PGF}_{2\alpha}$  in uterine epithelial cell proliferation.

### *Methods*

#### 5 *Patients and tissue collection*

Endometrial biopsies (n=12) at different stages of the menstrual cycle were collected with an endometrial suction curette (Pipelle, Laboratoire CCD, France) from women with regular menstrual cycles (25-35 days). In addition, full thickness endometrial biopsies (n=18) at all stages of the menstrual cycle (n=3 from early, mid and late proliferative and n=3 from early mid and late secretory) were collected from women undergoing hysterectomy for benign gynaecological indications. Shortly after pipelle suction or hysterectomy, tissue was either snap frozen in dry ice and stored at  $-70^{\circ}\text{C}$  (for RNA extraction), fixed in neutral buffered formalin (NBF) and wax embedded (for in-situ hybridisation studies), or placed in RPMI 1640 (containing 2 mmol/l L-glutamine, 100 U penicillin and 100  $\mu\text{g/ml}$  streptomycin) and transported to the laboratory for *in vitro* culture. All subjects reported regular menstrual cycles (cycle length 25-35 days) and no women had received a hormonal preparation in the 3 months preceding biopsy collection. Biopsies were dated according to stated last menstrual period (LMP) and confirmed by histological assessment according to criteria of Noyes and co-workers (20). Furthermore, circulating oestradiol and progesterone concentrations at the time of biopsy were consistent for both stated LMP and histological assignment of menstrual cycle stage. Ethical approval was obtained from Lothian Research Ethics Committee and written informed consent was obtained from all subjects before tissue collection.

#### *In situ hybridisation (ISH)*

Custom synthesis oligonucleotide double FITC-labelled cDNA probes for FP receptor were obtained from Biagnostik GmbH (Germany). Sections (5  $\mu$ m) were cut onto Gelatin coated Superfrost slides (BDH Laboratory Supplies, UK) from full thickness human uterine biopsies collected across the menstrual cycle (n=18). Tissue was dewaxed in xylene, rehydrated using increasing concentrations of ethanol before Proteinase K treatment (100  $\mu$ g/ml in Tris-HCl pH 7.6 100 mM containing EDTA 50 mM) for 15 min at 37°C to enhance cDNA probe access. After washing in DEPC-H<sub>2</sub>O, hybridisation mixture (50  $\mu$ l; supplied with probe) was added to each section and slides incubated for 4 h at 30°C before adding cDNA probe (6U/ml hybridisation mix) and incubating overnight at 30°C. Post-hybridisation washes of 1x SSC for 5 min (twice) and 0.1x SSC at 42°C for 15 min (twice) were completed before detecting the FITC-labelled probe using standard ICC reagents (TSA Biotin System, NEN Life Sciences, UK). Endogenous peroxidase activity was first blocked with 3% H<sub>2</sub>O<sub>2</sub> in methanol for 30 min before incubating sections with blocking buffer for 30 min. Conjugated anti-FITC-HRP (Boehringer-Mannheim, Check) was added in blocking buffer and the sections incubated for 60 min. After washing, biotinyl tyramide amplification reagent was applied to each slide and incubated for 15 min. Streptavidin-HRP was applied after washing and incubated for 30 min and probe localisation visualised with DAB. Control oligonucleotide double FITC-labelled cDNA probe containing the same proportion of cysteine (C) and guanine (G) bases as the FP receptor probe was included to assess background hybridisation. All treatments were carried out at room temperature unless otherwise specified.

#### 25 *Taqman quantitative RT-PCR*

Endometrial RNA samples were extracted from endometrial biopsies (n=33) using Tri-reagent (Sigma, UK) following the manufacturer's guidelines. Once extracted and quantified, RNA samples were reverse transcribed using MgCl<sub>2</sub> (5.5 mM), dNTPs (0.5 mM each), random hexamers (2.5  $\mu$ M), RNAase inhibitor

(0.4 U/ $\mu$ l) and multiscribe reverse transcriptase (1.25 U/ $\mu$ l; all from PE Biosystems, Warrington, UK). The mix was aliquoted into individual tubes (16  $\mu$ l/tube) and template RNA was added (4  $\mu$ l/tube of 100 ng/ $\mu$ l RNA). After mixing by brief centrifugation, samples were incubated for 90 minutes at 25°C, 5 45 minutes at 48°C and 95°C for 5 minutes. Thereafter cDNA samples were stored at -20°C. A tube with no reverse transcriptase was included to control for any DNA contamination.

To measure cDNA expression a reaction mix was prepared containing Taqman buffer (5.5 mM MgCl<sub>2</sub>, 200  $\mu$ M dATP, 200  $\mu$ M dCTP, 200  $\mu$ M dGTP, 400  $\mu$ M 10 dUTP), ribosomal 18S forward and reverse primers and probe (all at 50 nM), forward and reverse primers for EP receptor (300 nM), EP receptor probe (100 nM), AmpErase UNG (0.01 U/ $\mu$ l) and AmpliTaq Gold DNA Polymerase (0.025 U/ $\mu$ l; all from PE Biosystems). After mixing, 48  $\mu$ l was aliquoted into separate tubes and 2  $\mu$ l/replicate (40 ng) of cDNA added and mixed before placing 15 duplicate 24  $\mu$ l samples into a PCR plate. A no template control (containing water) was included in triplicate. Wells were sealed with optical caps and the PCR reaction carried out using an ABI Prism 7700. FP receptor primers and probe for quantitative PCR were designed using the PRIMER express program (PE Biosystems). The sequence of the FP receptor primers and probe were; 20 Forward 5'-GCA GCT GCG CTT CTT TCA A-3'; Reverse 5'-CAC TGT CAT GAA GAT TAC TGA AAA AAA TAC-3'; Probe (FAM labelled) 5'-CAC AAC CTG CCA GAC GGA AAA CCG-3'.

The ribosomal 18S primers and probe sequences were; Forward 5'-CGG CTA CCA CAT CCA AGG AA-3'; Reverse 5'-GCT GGA ATT ACC GCG GCT-3'; 25 Probe (VIC labelled) 5'-TGC TGG CAC CAG ACT TGC CCT C-3'. Data were analysed and processed using Sequence Detector v1.6.3 (PE Biosystems) as instructed by the manufacturer. Briefly, the software calculates the reaction cycle number at which fluorescence reaches a determined level for both 18S control and FP receptor. This is the relative abundance of FP receptor in each





The data reported herein is the first report of FP expression in human endometrium and demonstrates a potential role of  $\text{PGF}_{2\alpha}$  in uterine epithelial cell proliferation.

### *Methods*

#### 5 *Patients and tissue collection*

Endometrial biopsies (n=12) at different stages of the menstrual cycle were collected with an endometrial suction curette (Pipelle, Laboratoire CCD, France) from women with regular menstrual cycles (25-35 days). In addition, full thickness endometrial biopsies (n=18) at all stages of the menstrual cycle (n=3 from early, mid and late proliferative and n=3 from early mid and late secretory) were collected from women undergoing hysterectomy for benign gynaecological indications. Shortly after pipelle suction or hysterectomy, tissue was either snap frozen in dry ice and stored at  $-70^{\circ}\text{C}$  (for RNA extraction), fixed in neutral buffered formalin (NBF) and wax embedded (for in-situ hybridisation studies), or placed in RPMI 1640 (containing 2 mmol/l L-glutamine, 100 U penicillin and 100  $\mu\text{g/ml}$  streptomycin) and transported to the laboratory for *in vitro* culture. All subjects reported regular menstrual cycles (cycle length 25-35 days) and no women had received a hormonal preparation in the 3 months preceding biopsy collection. Biopsies were dated according to stated last menstrual period (LMP) and confirmed by histological assessment according to criteria of Noyes and co-workers (20). Furthermore, circulating oestradiol and progesterone concentrations at the time of biopsy were consistent for both stated LMP and histological assignment of menstrual cycle stage. Ethical approval was obtained from Lothian Research Ethics Committee and written informed consent was obtained from all subjects before tissue collection.

#### *In situ hybridisation (ISH)*



Custom synthesis oligonucleotide double FITC-labelled cDNA probes for FP receptor were obtained from Biognostik GmbH (Germany). Sections (5  $\mu$ m) were cut onto Gelatin coated Superfrost slides (BDH Laboratory Supplies, UK) from full thickness human uterine biopsies collected across the menstrual cycle (n=18). Tissue was dewaxed in xylene, rehydrated using increasing concentrations of ethanol before Proteinase K treatment (100  $\mu$ g/ml in Tris-HCl pH 7.6 100 mM containing EDTA 50 mM) for 15 min at 37°C to enhance cDNA probe access. After washing in DEPC-H<sub>2</sub>O, hybridisation mixture (50  $\mu$ l; supplied with probe) was added to each section and slides incubated for 4 h at 30°C before adding cDNA probe (6U/ml hybridisation mix) and incubating overnight at 30°C. Post-hybridisation washes of 1x SSC for 5 min (twice) and 0.1x SSC at 42°C for 15 min (twice) were completed before detecting the FITC-labelled probe using standard ICC reagents (TSA Biotin System, NEN Life Sciences, UK). Endogenous peroxidase activity was first blocked with 3% H<sub>2</sub>O<sub>2</sub> in methanol for 30 min before incubating sections with blocking buffer for 30 min. Conjugated anti-FITC-HRP (Boehringer-Mannheim, Check) was added in blocking buffer and the sections incubated for 60 min. After washing, biotinyl tyramide amplification reagent was applied to each slide and incubated for 15 min. Streptavidin-HRP was applied after washing and incubated for 30 min and probe localisation visualised with DAB. Control oligonucleotide double FITC-labelled cDNA probe containing the same proportion of cysteine (C) and guanine (G) bases as the FP receptor probe was included to assess background hybridisation. All treatments were carried out at room temperature unless otherwise specified.

#### 25 *Tagman quantitative RT-PCR*

Endometrial RNA samples were extracted from endometrial biopsies (n=33) using Tri-reagent (Sigma, UK) following the manufacturer's guidelines. Once extracted and quantified, RNA samples were reverse transcribed using MgCl<sub>2</sub> (5.5 mM), dNTPs (0.5 mM each), random hexamers (2.5  $\mu$ M), RNAase inhibitor

(0.4 U/ $\mu$ l) and multiscribe reverse transcriptase (1.25 U/ $\mu$ l; all from PE Biosystems, Warrington, UK). The mix was aliquoted into individual tubes (16  $\mu$ l/tube) and template RNA was added (4  $\mu$ l/tube of 100 ng/ $\mu$ l RNA). After mixing by brief centrifugation, samples were incubated for 90 minutes at 25°C, 5 45 minutes at 48°C and 95°C for 5 minutes. Thereafter cDNA samples were stored at -20°C. A tube with no reverse transcriptase was included to control for any DNA contamination.

To measure cDNA expression a reaction mix was prepared containing Taqman buffer (5.5 mM MgCl<sub>2</sub>, 200  $\mu$ M dATP, 200  $\mu$ M dCTP, 200  $\mu$ M dGTP, 400  $\mu$ M 10 dUTP), ribosomal 18S forward and reverse primers and probe (all at 50 nM), forward and reverse primers for EP receptor (300 nM), EP receptor probe (100 nM), AmpErase UNG (0.01 U/ $\mu$ l) and AmpliTaq Gold DNA Polymerase (0.025 U/ $\mu$ l; all from PE Biosystems). After mixing, 48  $\mu$ l was aliquoted into separate tubes and 2  $\mu$ l/replicate (40 ng) of cDNA added and mixed before placing 15 duplicate 24  $\mu$ l samples into a PCR plate. A no template control (containing water) was included in triplicate. Wells were sealed with optical caps and the PCR reaction carried out using an ABI Prism 7700. FP receptor primers and probe for quantitative PCR were designed using the PRIMER express program (PE Biosystems). The sequence of the FP receptor primers and probe were; 20 Forward 5'-GCA GCT GCG CTT CTT TCA A-3'; Reverse 5'-CAC TGT CAT GAA GAT TAC TGA AAA AAA TAC-3'; Probe (FAM labelled) 5'-CAC AAC CTG CCA GAC GGA AAA CCG-3'.

The ribosomal 18S primers and probe sequences were; Forward 5'-CGG CTA CCA CAT CCA AGG AA-3'; Reverse 5'-GCT GGA ATT ACC GCG GCT-3'; 25 Probe (VIC labelled) 5'-TGC TGG CAC CAG ACT TGC CCT C-3'. Data were analysed and processed using Sequence Detector v1.6.3 (PE Biosystems) as instructed by the manufacturer. Briefly, the software calculates the reaction cycle number at which fluorescence reaches a determined level for both 18S control and FP receptor. This is the relative abundance of FP receptor in each

sample and by comparing to an internal positive control, relative expression can be determined. Results are expressed as relative expression to the internal positive standard.

#### *Total Inositol Phosphate (InsP) Assays*

- 5 PGF<sub>2α</sub> stimulation of total InsP production was as described (21). Briefly, tissue samples or Ishikawa cells were incubated with inositol free DMEM containing 1% dialyzed heat-inactivated FCS and 0.5 μCi/well myo-[<sup>3</sup>H]inositol (Amersham Pharmacia Biotech) for 48 hours. Medium was removed, and cells washed with 1 ml buffer (140 mM NaCl, 20 mM HEPES, 4 mM KCl, 8 mM
- 10 glucose, 1 mM MgCl<sub>2</sub>, 1 mM CaCl<sub>2</sub>, 1 mg/ml bovine serum albumin) containing 10 mM LiCl. Cells were then incubated for 1 hour at 37°C in 1 ml buffer with or without inhibitors. Following incubation agonist was added at the required concentration and cells incubated for 1 hour. Reactions were terminated by the removal of agonist and the addition of 500 μl ice cold 10 mM formic acid, which
- 15 was incubated for 30 minutes at 4°C. Total [<sup>3</sup>H] inositol phosphates was separated from the formic acid cell extracts on AG 1-X8 anion exchange resin (Bio-Rad) and eluted with a 1 M ammonium formate/0.1 M formic acid solution. The associated radioactivity was determined by liquid scintillation counting and plotted relative to protein concentrations determined using the modified Lowry
- 20 method.

#### *Proliferation assay*

- Proliferation of Ishikawa cells was determined using a BrdU incorporation ELISA (Roche Diagnostics GmbH, Mannheim, Germany). Briefly, Ishikawa cells were seeded at 5 x 10<sup>3</sup> cells per well in a 96-well plate and allowed to
- 25 adhere overnight. Cells were next starved for 24 hr with indomethacin 1.5 μg/ml before 24 h PGF<sub>2α</sub> treatment (1nM – 1μM) in serum-free medium containing indomethacin. Inhibitors were added to cells for 60 min before PGF<sub>2α</sub> with the control well receiving the same concentration of vehicle. Following 24 h

treatment, cells were labelled with BrdU for 4 h, then fixed and assayed for BrdU incorporation using standard immunohistochemical techniques. Results were plotted as percentages of untreated cells.

### *Statistics*

- 5 Where appropriate, data were subjected to statistical analysis with ANOVA and Fishers PLSD tests (Statview 4.0; Abacus Concepts Inc., USA) and statistical significance accepted when  $p < 0.05$ .

### *Results*

- 10 FP receptor expression in human endometrium demonstrated a distinctive localisation pattern across the cycle. FP receptor localised to glandular epithelial cells in only mid- and late-proliferative stages of the menstrual cycle and was absent in all other biopsies examined. Only occasional expression was observed in perivascular cells and was independent of the cycle stage. In uterine adenocarcinoma biopsies FP receptor expression was also localised to epithelial  
15 cells. Epithelial cell expression of FP receptor was observed in all differentiation types with no discernible change in pattern between poor, moderately or well differentiated samples.

- Quantification of FP receptor mRNA expression in both endometrial and adenocarcinoma samples was determined by Taqman quantitative RT-PCR. A  
20 significant increase in relative FP receptor expression was observed in mid- to late-proliferative endometrium ( $0.40 \pm 0.02$ ;  $p \leq 0.05$ ) when compared to early proliferative ( $0.06 \pm 0.02$ ) and all secretory phases of the menstrual cycle ( $0.07 \pm 0.01$ ). Within human adenocarcinoma samples relative FP receptor mRNA expression was significantly increased ( $116.3 \pm 63.6$ ) compared to cycle  
25 endometrium ( $0.15 \pm 0.04$ ). No correlation was observed between the different grades of adenocarcinoma, however, a large variance was observed within these tissues.

Human endometrium produced a concentration-dependent increase in total InsP production following  $\text{PGF}_{2\alpha}$  treatment. Maximal InsP mobilisation was observed with  $\text{PGF}_{2\alpha}$  100nM and inhibited by pre-treatment with U73122 2 $\mu\text{M}$ , an inhibitor of PLC. Total inositol phosphate production was also measured in

5 Ishikawa cells following treatment with  $\text{PGF}_{2\alpha}$ .  $\text{PGF}_{2\alpha}$  produced a concentration dependent increase in total InsP with  $\text{PGF}_{2\alpha}$  100nM producing a maximum of 29 cpm/mg protein.

Treatment of Ishikawa cells with  $\text{PGF}_{2\alpha}$  100nM induced phosphorylation of extracellular regulated kinase (ERK) in Ishikawa cells. Treatment for 10 min

10 with  $\text{PGF}_{2\alpha}$  100 nM induced  $6.6 \pm 0.7$  fold increase in phosphorylated ERK intensity compared to native ERK.

The proliferative effect of  $\text{PGF}_{2\alpha}$  in Ishikawa cells was determined by measuring incorporation of BrdU.  $\text{PGF}_{2\alpha}$  produced a concentration-dependent increase in BrdU incorporation that was maximal at 100 nM ( $136.3 \pm 7.48\%$ ). Pre-

15 treatment of cells with an ERK1/2 inhibitor (PD98059 50 $\mu\text{M}$ ) produced a reduction in basal proliferation ( $84.0 \pm 5.8\%$ ) although  $\text{PGF}_{2\alpha}$  still produced a concentration-dependent increase in proliferation in the presence of PD98059 50 $\mu\text{M}$  (100nM  $\text{PGF}_{2\alpha}$ -induced  $119.4 \pm 11.2\%$  control BrdU incorporation). Pre-incubation with an inhibitor of PLCB (U73122 2 $\mu\text{M}$ ) also produced a slight

20 reduction in basal proliferation ( $93.9 \pm 1.9\%$ ), and in addition, inhibited the concentration-dependent increase in proliferation following  $\text{PGF}_{2\alpha}$  ( $106.1 \pm 6.6\%$  BrdU incorporation by 100nM  $\text{PGF}_{2\alpha}$ ).

*Discussion*

We have demonstrated increased expression of FP receptor in epithelial cells from proliferative endometrium and different grades of adenocarcinoma. Moreover, we have quantified and demonstrated functional FP receptor expression in Ishikawa cells of human endometrial adenocarcinoma origin. In Ishikawa cells,  $\text{PGF}_{2\alpha}$  induced  $\text{IP}_3$  production and phosphorylation of p42/p44 MAPK (ERK). Additionally, following overnight incubation with  $\text{PGF}_{2\alpha}$ , Ishikawa cells demonstrated increased cell proliferation that was inhibited by PLC blockade.

- 10  $\text{PGF}_{2\alpha}$  has not previously been demonstrated to have a role in cell proliferation of mammalian tissues. Studies to identify whether  $\text{PGF}_{2\alpha}$  was involved in colon adenocarcinomas demonstrated a lack of proliferation by  $\text{PGF}_{2\alpha}$  in HCT-8 and HT-29 human colon adenocarcinoma cell lines. FP receptor knockout mice do not demonstrate any abnormalities in endometrial physiology but instead  
15 demonstrate failures in myometrial function with females being unable to deliver pups at term (22).

The data disclosed herein is the first demonstration of the proliferative effects of  $\text{PGF}_{2\alpha}$  in human endometrial epithelial cells. Maximal FP receptor expression is observed in mid-late proliferative endometrium when oestrogen levels are  
20 elevated.

Without being bound by theory, it is believed that the high FP receptor expression observed in adenocarcinoma samples could relate to levels of progesterone receptors where the ratio of  $\text{PR}_A$ :  $\text{PR}_B$  may be important in endometrial cancer (23). In reproductive tissue carcinomas, such as breast, endometrium and ovary,  
25 oestrogens promote cell proliferation and are implicated in disease progression (24). In the endometrium, progesterone opposes the proliferative effect of oestrogen by promoting cell differentiation and progestin treatment has proved beneficial in the management of endometrial cancer (23, 25). However,



therapeutic benefit is observed only when these tumours express functional progesterone receptors (PR) (25) and combining progestins with oestrogen in hormone replacement therapy (HRT), to increase PR expression, has been found to decrease the risk of endometrial cancer (26, 27). As such, loss of  
5 responsiveness to progesterone could result in loss of progesterone inhibition and explain the observed increase in FP receptor expression observed in uterine adenocarcinoma.

Ishikawa, an endometrial epithelial cell, expresses greater levels of FP receptor than normal endometrium and is responsive to  $\text{PGF}_{2\alpha}$ . We observed  
10 mobilisation of InsP and phosphorylation of ERK in these cells following  $\text{PGF}_{2\alpha}$  as has been previously identified (28, 29). Moreover,  $\text{PGF}_{2\alpha}$  induced increased proliferation in Ishikawa cells that was sensitive to PLC blockade. This is the first documented report showing epithelial cell proliferation in response to  $\text{PGF}_{2\alpha}$ . These observations support the role of  $\text{PGF}_{2\alpha}$  in normal epithelial cell  
15 proliferation and endometrial adenocarcinoma where FP receptor expression is increased.

In summary, this is the first publication to demonstrate FP receptor expression and localisation with human endometrial tissue and human endometrial adenocarcinomas. We have demonstrated epithelial cell expression for FP  
20 receptor and have also demonstrated increased proliferation in endometrial epithelial cells, Ishikawa, following  $\text{PGF}_{2\alpha}$ . These studies clearly indicate a role for  $\text{PGF}_{2\alpha}$  in epithelial cell proliferation and suggest this is one mechanism by which NSAID therapy can reduce endometrial cell proliferation and progression of endometrial cancers.

25

**Example 2: Treatment of uterine cancer with FP receptor antagonist.**

A patient suffering from uterine cancer is administered AL-3138 or AL-8810 at a dosing quantity and frequency such that the therapeutic level of active agent at the site of treatment is maintained at a level ideally EC90 but preferably not less than EC50 throughout the treatment period. The treatment is delivered orally or  
5 more locally depending on patient acceptability, avoidance of side effects and systemic bioavailability.

**Example 3: Treatment of uterine cancer with an FP receptor antagonist and an EP2 receptor antagonist.**

A patient suffering from uterine cancer is administered AL-3138 or AL-8810 and  
10 AH6809 at a dosing quantity and frequency such that the therapeutic level of active agent at the site of treatment is maintained at a level ideally EC90 but preferably not less than EC50 throughout the treatment period. The treatment is delivered orally or more locally depending on patient acceptability, avoidance of side effects and systemic bioavailability.

15 **Example 4: Treatment of uterine cancer with an FP receptor antagonist and an EP4 receptor antagonist.**

A patient suffering from uterine cancer is administered AL-3138 or AL-8810 and  
AH23848B at a dosing quantity and frequency such that the therapeutic level of each active agent at the site of treatment is maintained at a level ideally EC90 but  
20 preferably not less than EC50 throughout the treatment period. The treatment is delivered orally or more locally depending on patient acceptability, avoidance of side effects and systemic bioavailability.

**Example 5: Treatment of fibroids with an FP receptor antagonist**

A patient suffering from fibroids is administered AL-3138 or AL-8810 at a  
25 dosing quantity and frequency such that the therapeutic level of active agent at the site of treatment is maintained at a level ideally EC90 but preferably not less than EC50 throughout the treatment period. The treatment is delivered orally or

more locally depending on patient acceptability, avoidance of side effects and systemic bioavailability.

**Example 6: Treatment of fibroids with an FP receptor antagonist and an EP2 receptor antagonist.**

- 5 A patient suffering from fibroids is administered AL-3138 or AL-8810 and AH6809 at a dosing quantity and frequency such that the therapeutic level of each active agent at the site of treatment is maintained at a level ideally EC90 but preferably not less than EC50 throughout the treatment period. The treatment is delivered orally or more locally depending on patient acceptability, avoidance of
- 10 side effects and systemic bioavailability.

**Example 7: Treatment of fibroids with an FP receptor antagonist and an EP4 receptor antagonist.**

- 15 A patient suffering from fibroids is administered AL-3138 or AL-8810 and AH22921 at a dosing quantity and frequency such that the therapeutic level of each active agent at the site of treatment is maintained at a level ideally EC90 but preferably not less than EC50 throughout the treatment period. The treatment is delivered orally or more locally depending on patient acceptability, avoidance of side effects and systemic bioavailability.

**Example 8: Treatment of endometriosis with FP receptor antagonist**

- 20 A patient suffering from endometriosis is administered AL-3138 or AL-8810 at a dosing quantity and frequency such that the therapeutic level of active agent at the site of treatment is maintained at a level ideally EC90 but preferably not less than EC50 throughout the treatment period. The treatment is delivered orally or more locally depending on patient acceptability, avoidance of side effects and
- 25 systemic bioavailability.

**Example 9: Treatment of endometriosis with an FP receptor antagonist and an EP2 receptor antagonist.**

A patient suffering from endometriosis is administered AL-3138 or AL-8810 and AH6809 at a dosing quantity and frequency such that the therapeutic level of each active agent at the site of treatment is maintained at a level ideally EC90 but preferably not less than EC50 throughout the treatment period. The treatment is delivered orally or more locally depending on patient acceptability, avoidance of side effects and systemic bioavailability.

**Example 10: Treatment of endometriosis with an FP receptor antagonist and an EP4 receptor antagonist.**

A patient suffering from endometriosis is administered AL-3138 or AL-8810 and AH2291 at a dosing quantity and frequency such that the therapeutic level of each active agent at the site of treatment is maintained at a level ideally EC90 but preferably not less than EC50 throughout the treatment period. The treatment is delivered orally or more locally depending on patient acceptability, avoidance of side effects and systemic bioavailability.

**References for Example 1**

1. Narumiya, S. and FitzGerald, G. A. Genetic and pharmacological analysis of prostanoid receptor function. *J Clin Invest*, 108: 25-30., 2001.
2. Coleman, R. A., Smith, W. L., and Narumiya, S. International Union of Pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes. *Pharmacol Rev*, 46: 205-229, 1994.
3. Vane, J. R., Bakhle, Y. S., and Botting, R. M. Cyclooxygenases 1 and 2. *Annu Rev Pharmacol Toxicol*, 38: 97-120, 1998.
4. Yokoyama, C., Miyata, A., Ihara, H., Ullrich, V., and Tanabe, T. Molecular cloning of human platelet thromboxane A synthase. *Biochem Biophys Res Commun*, 178: 1479-1484, 1991.

5. Suzuki-Yamamoto, T., Nishizawa, M., Fukui, M., Okuda-Ashitaka, E., Nakajima, T., Ito, S., and Watanabe, K. cDNA cloning, expression and characterization of human prostaglandin F synthase. *FEBS Lett*, 462: 335-340, 1999.
- 5 6. Miyata, A., Hara, S., Yokoyama, C., Inoue, H., Ullrich, V., and Tanabe, T. Molecular cloning and expression of human prostacyclin synthase. *Biochem Biophys Res Commun*, 200: 1728-1734, 1994.
7. Kanaoka, Y., Ago, H., Inagaki, E., Nanayama, T., Miyano, M., Kikuno, R., Fujii, Y., Eguchi, N., Toh, H., Urade, Y., and Hayaishi, O. Cloning and  
10 crystal structure of hematopoietic prostaglandin D synthase. *Cell*, 90: 1085-1095, 1997.
8. Forsberg, L., Leeb, L., Thoren, S., Morgenstern, R., and Jakobsson, P. Human glutathione dependent prostaglandin E synthase: gene structure and regulation. *FEBS Lett*, 471: 78-82, 2000.
- 15 9. Tsujii, M., Kawano, S., Tsuji, S., Sawaoka, H., Hori, M., and DuBois, R. N. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. *Cell*, 93: 705-716, 1998.
10. Van Voorhis, B. J., Huettner, P. C., Clark, M. R., and Hill, J. A. Immunohistochemical localization of prostaglandin H synthase in the female  
20 reproductive tract and endometriosis. *Am J Obstet Gynecol*, 163: 57-62, 1990.
11. Rees, M. C., Parry, D. M., Anderson, A. B., and Turnbull, A. C. Immunohistochemical localisation of cyclooxygenase in the human uterus. *Prostaglandins*, 23: 207-214, 1982.
12. Rees, M. C., Anderson, A. B., Demers, L. M., and Turnbull, A. C.  
25 Endometrial and myometrial prostaglandin release during the menstrual cycle in relation to menstrual blood loss. *J Clin Endocrinol Metab*, 58: 813-818, 1984.

13. Jones, R. L., Kelly, R. W., and Critchley, H. O. D. Chemokine and cyclooxygenase-2 expression in human endometrium coincides with leukocyte accumulation. *Hum Reprod*, 12: 1300-1306, 1997.
14. Marions, L. and Danielsson, K. G. Expression of cyclo-oxygenase in  
5 human endometrium during the implantation period. *Mol Hum Reprod*, 5: 961-965, 1999.
15. Abel, M. H. and Baird, D. T. The effect of 17 $\beta$ -estradiol and progesterone on prostaglandin production by human endometrium maintained in organ culture. *Endocrinology*, 106: 1599-1606, 1980.
- 10 16. Fortier, M. A., Guilbault, L. A., and Grasso, F. Specific properties of epithelial and stromal cells from the endometrium of cows. *J Reprod Fertil*, 83: 239-248., 1988.
17. Ou, C. W., Chen, Z. Q., Qi, S., and Lye, S. J. Expression and regulation of the messenger ribonucleic acid encoding the prostaglandin F(2alpha) receptor  
15 in the rat myometrium during pregnancy and labor. *Am J Obstet Gynecol*, 182: 919-925., 2000.
18. Dong, Y. L. and Yallampalli, C. Pregnancy and exogenous steroid treatments modulate the expression of relaxant EP(2) and contractile FP receptors in the rat uterus. *Biol Reprod*, 62: 533-539., 2000.
- 20 19. Hoyer, P. B., Marion, S. L., Stine, I., Rueda, B. R., Hamernik, D. L., Regan, J. W., and Wise, M. E. Ovine prostaglandin F2alpha receptor: steroid influence on steady-state levels of luteal mRNA. *Endocrine*, 10: 105-111., 1999.
20. Noyes, R. W., Hertig, A. T., and Rock, J. Dating the endometrial biopsy. *Fertil Steril*, 1: 3-25, 1950.

21. Berg, K. A., Clarke, W. P., Sailstad, C., Saltzman, A., and Maayani, S. Signal transduction differences between 5-hydroxytryptamine type 2A and type 2C receptor systems. *Mol Pharmacol*, 46: 477-484., 1994.
22. Sugimoto, Y., Yamasaki, A., Segi, E., Tsuboi, K., Aze, Y., Nishimura, T.,  
5 Oida, H., Yoshida, N., Tanaka, T., Katsuyama, M., Hasumoto, K., Murata, T.,  
Hirata, M., Ushikubi, F., Negishi, M., Ichikawa, A., and Narumiya, S. Failure of  
parturition in mice lacking the prostaglandin F receptor. *Science*, 277: 681-683.,  
1997.
23. Kumar, N. S., Richer, J., Owen, G., Litman, E., Horwitz, K. B., and  
10 Leslie, K. K. Selective down-regulation of progesterone receptor isoform B in  
poorly differentiated human endometrial cancer cells: implications for  
unopposed estrogen action. *Cancer Res*, 58: 1860-1865., 1998.
24. Persson, I. Estrogens in the causation of breast, endometrial and ovarian  
cancers - evidence and hypotheses from epidemiological findings. *J Steroid*  
15 *Biochem Mol Biol*, 74: 357-364., 2000.
25. Sasaki, M., Dharia, A., Oh, B. R., Tanaka, Y., Fujimoto, S., and Dahiya,  
R. Progesterone receptor B gene inactivation and CpG hypermethylation in  
human uterine endometrial cancer. *Cancer Res*, 61: 97-102., 2001.
26. Dai, D., Kumar, N. S., Wolf, D. M., and Leslie, K. K. Molecular tools to  
20 reestablish progestin control of endometrial cancer cell proliferation. *Am J*  
*Obstet Gynecol*, 184: 790-797., 2001.
27. Lim, C. S., Baumann, C. T., Htun, H., Xian, W., Irie, M., Smith, C. L.,  
and Hager, G. L. Differential localization and activity of the A- and B-forms of  
the human progesterone receptor using green fluorescent protein chimeras. *Mol*  
25 *Endocrinol*, 13: 366-375., 1999.
28. Chen, D. B., Westfall, S. D., Fong, H. W., Roberson, M. S., and Davis, J.  
S. Prostaglandin F2alpha stimulates the Raf/MEK1/mitogen-activated protein

kinase signaling cascade in bovine luteal cells. *Endocrinology*, 139: 3876-3885., 1998.

29. Stocco, C. O., Lau, L. F., and Gibori, G. A calcium/calmodulin-dependent activation of ERK1/2 mediates JunD phosphorylation and induction of nur77 and 20alpha-hsd genes by prostaglandin F2alpha in ovarian cells. *J Biol Chem*, 277: 3293-3302., 2002.

#### Further References

- Ashby, B. (1998) Co-expression of prostaglandin receptors with opposite effects: a model for homeostatic control of autocrine and paracrine signalling. *Biochem Pharmacol* 55: 239-246.
- 10 Coleman, RA, Smith, WL, Narumiya, S. (1994) International Union of Pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes. *Pharmacol Rev* 46: 205-229.
- 15 DeWitt, DL. (1991) Prostaglandin endoperoxide synthase: regulation of enzyme expression. *Biochim Biophys Acta* 1083: 121-134.
- Gordon, MD, Ireland, K. (1994) Pathology of hyperplasia and carcinoma of the endometrium. *Semin Oncol* 21: 64-70.
- Herschman, HR. (1996) Prostaglandin synthase 2. *Biochim Biophys Acta* 1299: 125-140.
- 20 Mant, JW, Vessey, MP. (1994) Ovarian and endometrial cancers. *Cancer Surv* 20: 287-307.
- Subbaramaiah, K, Telang, N, Ramonetti, JT, Araki, R, DeVito, B, Weksler, BB, Dannenberg, AJ. (1996) Transcription of cyclooxygenase-2 is enhanced in transformed mammary epithelial cells. *Cancer Res* 56: 4424-4429.
- 25



**CLAIMS**

1. A method of treating or preventing a pathological condition of the uterus in a female individual, the method comprising administering to the individual at least one agent that prevents  $\text{PGF}_{2\alpha}$  having its effect on the FP receptor.
2. A method according to Claim 1 wherein the pathological condition of the uterus is associated with abnormal growth of cells of the myometrium or endometrium.
3. A method according to Claim 1 or 2 wherein the pathological condition of the uterus is uterine carcinoma or an endometrial or myometrial pathological condition.
4. A method according to Claim 3 wherein the endometrial pathological condition is endometriosis.
5. A method according to Claim 3 wherein the myometrial pathological condition is fibroids.
6. A method according to any one of Claims 1 to 5 wherein the agent that prevents  $\text{PGF}_{2\alpha}$  having its effect on the FP receptor prevents or reduces the binding of  $\text{PGF}_{2\alpha}$  to the FP receptor.
7. A method according to any one of Claims 1 to 6 wherein the agent that prevents  $\text{PGF}_{2\alpha}$  having its effect on the FP receptor affects the interaction between  $\text{PGF}_{2\alpha}$  and the FP receptor, or the interaction between the FP receptor and the associated  $G_{\alpha q}$  protein, thus inhibiting or disrupting a  $\text{PGF}_{2\alpha}$ -FP mediated signal transduction pathway.
8. A method according to any one of Claims 1 to 7 wherein the agent is an antagonist of the FP receptor.

9. A method according to Claim 8 wherein the FP receptor antagonist is any one or more of PGF<sub>2α</sub> dimethyl amide; PGF<sub>2α</sub> dimethyl amine; AL-8810 ((5Z,13E)-(9S,11S,15R)-9, 15-dihydroxy-11-fluoro-15-(2-indanyl)-16,17,18,19,20-pentanor-5,13-prostadienoic acid); AL-3138 (11-deoxy-16-fluoro PGF<sub>2α</sub>); phloretin; glibenclamide; ridogrel; PHG113; PCP-1 (RVKFKSQHRQGRSHLEM); PCP-2 (RKAVLKNLYKLASQCCGVHVISLHIWELSSIKNSLKVA AIS ESPV AEKSAST); PCP-3 (CLSEEAKEARRINDEIERQLRRDKRDARRE-NH<sub>2</sub>); PCP-4 (KDTILQLNLKEYNLV-NH<sub>2</sub>); PCP-8 (ilghrdyk); PCP-10 (wedrfyll); PCP-13 (ILGHRDYK); PCP-14 (YQDRFYLL); (ILAHRDYK); PCP-13.7 (ILAHRDYK); PCP-13.8 (ILaHRDYK); PCP-13.11 (ILGFRDYK); PCP-13.13 (ILGHKDYK); PCP-13.14 (ILGHRNYK); PCP-13.18 (ILGHQDYK); PCP-13.20 (ILGHRDY-amide); PCP-13.21 (ILGHRDYK-amide); PCP-13.22 (ILGWRDYK); PCP-13.24 (ILGXRDYK); and PCP-15 (SNVLC SIF).
10. A method according to any one of Claims 1 to 7 wherein the agent is an antagonist of PGF<sub>2α</sub>.
11. A method according to Claim 10 wherein the PGF<sub>2α</sub> antagonist is an anti-PGF<sub>2α</sub> antibody.
12. A method according to any of Claims 1 to 11 wherein an inhibitor of PGES and/or an antagonist of EP2 or EP4 is also administered to the individual.
13. A method according to Claim 12 wherein the antagonist of EP2 or EP4 is one or more of AH6809, an omega-substituted prostaglandin E derivative described in WO 00/15608 (Ono Pharm Co Ltd), AH23848B, AH22921X, IFTSYLECL, IFASYECL, IFTSABCL, IFTSYEAL, ILASYECL, IFTSTDCL, TSYEAL (with 4-biphenylalanine), TSYEAL (with homophenylalanine), a 5-thia-prostaglandin E derivative described

in WO 00/03980 (Ono Pharm Co Ltd), 5-butyl-2,4-dihydro-4-[[2'-[N-(3-chloro-2-thiophenecarbonyl)sulfamoyl]biphenyl-4-yl]methyl]-2-{2-(trifluoromethyl)phenyl]-1,2,4-triazol-3-one potassium salt, 5-butyl-2,4-dihydro-4-[[2'-[N-(2-methyl-3-furoyl)sulfamoyl]biphenyl-4-yl]methyl]-2-{2-(trifluoromethyl)phenyl]-1,2,4-triazol-3-one, 5-butyl-2,4-dihydro-4-[[2'-[N-(3-methyl-2-thiophenecarbonyl)sulfamoyl]biphenyl-4-yl]methyl]-2-{2-(trifluoromethyl)phenyl]-1,2,4-triazol-3-one, 5-butyl-2,4-dihydro-4-[[2'-[N-(2-thiophenecarbonyl)sulfamoyl]biphenyl-4-yl]methyl]-2-{2-(trifluoromethyl)phenyl]-1,2,4-triazol-3-one, and 5-butyl-2,4-dihydro-4-[[2'-[N-[2-(methypyrrole)carbonyl]sulfamoyl]biphenyl-4-yl]methyl]-2-{2-(trifluoromethyl)phenyl]-1,2,4-triazol-3-one.

14. Use of at least one agent that prevents  $\text{PGF}_{2\alpha}$  having its effect on the FP receptor, in the manufacture of a medicament for treating or preventing a pathological condition of the uterus in a female individual.
15. Use according to Claim 14, wherein the individual is administered an inhibitor of PGES and/or an antagonist of EP2 or EP4.
16. Use of an inhibitor of PGES and/or an antagonist of EP2 or EP4 in the manufacture of a medicament for treating or preventing a pathological condition of the uterus in a female individual, wherein the individual is administered at least one agent that prevents  $\text{PGF}_{2\alpha}$  having its effect on the FP receptor.
17. Use of a combination of at least one agent that prevents  $\text{PGF}_{2\alpha}$  having its effect on the FP receptor, and an inhibitor of PGES and/or an antagonist of EP2 or EP4, in the manufacture of a medicament for treating or preventing a pathological condition of the uterus in a female individual.

18. Use according to any one of Claims 14-17 wherein the pathological condition of the uterus is uterine carcinoma or an endometrial or myometrial pathological condition.
19. A pharmaceutical composition comprising at least one agent that prevents  $\text{PGF}_{2\alpha}$  having its effect on the FP receptor for treating or preventing a pathological condition of the uterus in a female individual.
20. A pharmaceutical composition according to Claim 19 and also comprising an inhibitor of PGES and/or an antagonist of EP2 or EP4.
21. A pharmaceutical composition according to Claim 19 or 20 wherein the pathological condition of the uterus is uterine carcinoma or an endometrial or myometrial pathological condition.
22. A vaginal ring or a tampon or an intrauterine device comprising at least one agent that prevents  $\text{PGF}_{2\alpha}$  having its effect on the FP receptor.
23. A vaginal ring or a tampon or an intrauterine device according to Claim 22 wherein the agent comprises an antagonist of the FP receptor.
24. A vaginal ring or a tampon or an intrauterine device according to Claim 23 wherein the FP receptor antagonist comprises any one or more of  $\text{PGF}_{2\alpha}$  dimethyl amide;  $\text{PGF}_{2\alpha}$  dimethyl amine; AL-8810 ((5Z,13E)-(9S,11S,15R)-9, 15-dihydroxy-11-fluoro-15-(2-indanyl)-16,17,18,19,20-pentanoic-5,13-prostadienoic acid); AL-3138 (11-deoxy-16-fluoro  $\text{PGF}_{2\alpha}$ ); phloretin; glibenclamide; ridogrel; PHG113; PCP-1 (RVKFKSQQHRQGRSHHLEM); PCP-2 (RKAVLKNLYKLASQCCGVHVISLHIWELSSIKNSLKVAAISESPV ARKSAST); PCP-3 (CLSEEAKEARRINDEIERQLRRDKRDARRE-NH<sub>2</sub>); PCP-4 (KDTILQLNLKEYNLV-NH<sub>2</sub>); PCP-8 (ilghrdyk); PCP-10 (wedrfyll); PCP-13 (ILGHRDYK); PCP-14 (YQDRFYLL); (ILAHRDYK); PCP-13.7 (ILAHRDYK); PCP-13.8 (ILaHRDYK); PCP-

13.11 (ILGFRDYK); PCP-13.13 (ILGHKDYK); PCP-13.14 (ILGHRNYK); PCP-13.18 (ILGHQDYK); PCP-13.20 (ILGHRDY-amide); PCP-13.21 (ILGHRDYK-amide); PCP-13.22 (ILGWRDYK); PCP-13.24 (ILGXRDYK); and PCP-15 (SNVLCSIF).

25. A vaginal ring or a tampon or an intrauterine device according to Claim 22 wherein the agent comprises an antagonist of  $\text{PGF}_{2\alpha}$ .
26. A vaginal ring or a tampon or an intrauterine device according to Claim 25 wherein the  $\text{PGF}_{2\alpha}$  antagonist comprises anti- $\text{PGF}_{2\alpha}$  antibodies.
27. A vaginal ring or a tampon or an intrauterine device according to any one of Claims 22 to 26 further comprising an inhibitor of PGES and/or an antagonist of EP2 or EP4.
28. A vaginal ring or a tampon or an intrauterine device according to Claim 27 wherein the antagonist of EP2 or EP4 is one or more of AH6809, an omega-substituted prostaglandin E derivative described in WO 00/15608 (Ono Pharm Co Ltd), AH23848B, AH22921X, IFTSYLECL, IFASYECL, IFTSAECL, IFTSYEAL, ILASYECL, IFTSTDCL, TSYEAL (with 4-biphenylalanine), TSYEAL (with homophenylalanine), a 5-thia-prostaglandin E derivative described in WO 00/03980 (Ono Pharm Co Ltd), 5-butyl-2,4-dihydro-4-[[2'-[N-(3-chloro-2-thiophenecarbonyl)sulfamoyl]biphenyl-4-yl]methyl]-2-{2-(trifluoromethyl)phenyl]-1,2,4-triazol-3-one potassium salt, 5-butyl-2,4-dihydro-4-[[2'-[N-(2-methyl-3-furoyl)sulfamoyl]biphenyl-4-yl]methyl]-2-{2-(trifluoromethyl)phenyl]-1,2,4-triazol-3-one, 5-butyl-2,4-dihydro-4-[[2'-[N-(3-methyl-2-thiophenecarbonyl)sulfamoyl]biphenyl-4-yl]methyl]-2-{2-(trifluoromethyl)phenyl]-1,2,4-triazol-3-one, 5-butyl-2,4-dihydro-4-[[2'-[N-(2-thiophenecarbonyl)sulfamoyl]biphenyl-4-yl]methyl]-2-{2-(trifluoromethyl)phenyl]-1,2,4-triazol-3-one, and 5-butyl-2,4-dihydro-4-

[[2'-[N-[2-(methypyrrole)carbonyl]sulfamoyl]biphenyl-4-yl]methyl]-2-(2-(trifluoromethyl)phenyl)-1,2,4-triazol-3-one.

29. A composition comprising at least one agent that prevents  $\text{PGF}_{2\alpha}$  having its effect on the FP receptor, and an inhibitor of PGES and/or an antagonist of EP2 or EP4.
30. A pharmaceutical composition comprising at least one agent that prevents  $\text{PGF}_{2\alpha}$  having its effect on the FP receptor, and an inhibitor of PGES and/or an antagonist of EP2 or EP4, and a pharmaceutically acceptable carrier.
31. A composition according to Claim 29 for use in medicine.

**ABSTRACT**

**TREATMENT METHODS** of diseases of the uterus

A method of treating or preventing a pathological condition of the uterus in an female individual, the method comprising administering to the individual at least one agent that prevents  $\text{PGF}_{2\alpha}$  having its effect on the FP receptor

Typically, the pathological condition is uterine cancer, fibroids or endometriosis.

~~Figure no. 2~~

Figure 1: FP in-situ hybridisation in human endometrium and adenocarcinoma






Figure 1: FP in-situ hybridisation in human endometrium and adenocarcinoma




Figure 2: FP mRNA expression




Figure 3: Total InsP mobilisation in endometrium (n=2)




Figure 4: PGF<sub>2α</sub>-induced ERK phosphorylation





Figure 5: PGF<sub>2α</sub>-induced BrdU incorporation



**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**